A cannabis testing company is gearing up for regulatory changes in California and looking ahead into the Canadian market as the lab industry appears poised for growth alongside the overall space.

On Monday (April 30), EVIO (OTCQB:EVIO), a cannabis testing company, expanded its presence in California thanks to the acquisition of Leaf Detective, a testing lab company based in Humboldt County.


William Waldrop, CEO of EVIO, said in a statement that Leaf Detective’s facilities will be upgraded to meet new testing standards, and are set to be operational by the end of the third quarter.

This acquisition was key for EVIO as Leaf Detective holds one of the 28 testing facility licenses from the Bureau of Cannabis Control in California.

The license is even more critical given that California is about to change its marijuana laws, making it mandatory for all legal cannabis sold in the state to be tested and approved by these specific labs.

“What’s happening is as of July 1, any [cannabis] product that’s sold in California dispensaries is supposed to be tested, and they should have [a] certificate of analysis confirming that,” Waldrop told the Investing News Network (INN).

He said exceptions have been given to any product grown before December 31 last year, during the first six months of 2018, but that will disappear in July.

The executive told INN that EVIO is attempting to encourage the cannabis industry in California to start testing or seeking retests for products currently on the shelf to guarantee full compliance in the state.

Waldrop added that part of the goal of the Leaf Detective acquisition was to secure a footprint in the Northern California area. While the company will have to update the facilities of the acquisition before the July 1 date, EVIO will still be able to conduct its testing despite the planned upgrades.

Cannabis testing business model

When asked how much an ancillary business like lab testing co-relates to growth in the overall cannabis business, Waldrop said he sees a US$200-million opportunity just in California for testing.

“In California right now there is about a $2.5-billion medical economy … testing will be about [a] $100-million opportunity just in California just for the medical side,” he said.

In terms of the Canadian market, for which EVIO prepared an acquisition for half of Alberta-based Keystone Labs, Waldrop sees an opportunity for $250 to $300 million per year for lab testers, based on data from business research firm Deloitte.

Waldrop told INN there is potential for EVIO to list on a Canadian exchange. He believes the Canadian Securities Exchange is the only legal option the company has after an examination.

“We’ve known that there’s been a need for multiple labs throughout the US, specifically for EVIO and targeting immediate opportunities, the majority of our growth is targeted to be in California,” he said.

Testing standards in California and Canada

Waldrop explained these tests are made to find deficiencies in cannabis products with examinations of cannabinoids, moisture content, full scale for residual solid and pesticides.

He told INN the company is expecting Health Canada, the agency tasked with regulating cannabis in the country, to affirm which pesticides will be mandated to test in all cannabis.

“What we are hearing [is] they are probably going to be very similar to California as it relates to the breadth and the scope of the types of pesticides that will be required to be tested in Canada,” he said.

Investor takeaway

So far in 2018, EVIO’s share price has seen a dip of 22.9 percent. Wednesday (May 2) at the end of the trading session, EVIO was valued at $1.63 per share on the OTCQB, based on a 1.21-percent reduction.

In his initial research report on the company, Jim Marrone, analyst with Singular Research, gave the company a “buy” rating and set a 12-month price target of $2.

“We believe EVIO is positioned to benefit as more states look to legalize cannabis and mandate testing of products from accredited laboratories,” Marrone wrote in his report.

The analyst warned investors of delays in EVIO’s execution of its currently proposed expansion plans, and of the potential for regulations to affect the growth trajectory of the cannabis testing market.

Waldrop told INN that EVIO is on pace to operate 18 modern cannabis testing facilities by the end of 2018, with the majority in California.

“Our recommendation is based on an expectation that regulatory environment continues to remain favorable and the management can execute on the growth plan it has outlined,” Marrone wrote.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less